Barrett & Company’s Esperion Therapeutics ESPR Stock Holding History

Barrett & Company’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-300	Closed	-$295	–	647
2025 Q2	$295	Hold	300	–	–	﹤0.01%	628
2025 Q1	$432	Hold	300	–	–	﹤0.01%	605
2024 Q4	$660	Hold	300	–	–	﹤0.01%	590
2024 Q3	$495	Hold	300	–	–	﹤0.01%	564
2024 Q2	$666	Hold	300	–	–	﹤0.01%	573
2024 Q1	$804	Hold	300	–	–	﹤0.01%	583
2023 Q4	$897	Hold	300	–	–	﹤0.01%	572
2023 Q3	$294	Hold	300	–	–	﹤0.01%	608
2023 Q2	$417	Hold	300	–	–	﹤0.01%	584
2023 Q1	$477	Hold	300	–	–	﹤0.01%	566
2022 Q4	$1.87K	Hold	300	–	–	﹤0.01%	519
2022 Q3	$1.87K	Buy	+300	New	+$2.06K	﹤0.01%	519

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Barrett & Company's ESPR Position: Q3 2025 in Review

Barrett & Company sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 300 shares — an estimated $295 sold.

Barrett & Company first reported a position in ESPR in Q3 2022 and held it in 12 quarters. The position peaked at $1.87K in Q4 2022. 189 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

Barrett & Company reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
Barrett & Company sold 300 Esperion Therapeutics shares in Q3 2025, an estimated $295.
Barrett & Company first reported a position in Esperion Therapeutics in Q3 2022 and held it in 12 quarters.
Barrett & Company's Esperion Therapeutics position peaked at $1.87K in Q4 2022.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Barrett & Company's 13F filing for Q3 2025, filed 31 Oct 2025.